1.Efficacy of the cat deafening method: Co-administration of ethacrynic acid and kanamycin.
Jang JH1, Lee HS2, Oh SH3,4, Park MH2. Acta Otolaryngol. 2016 Mar;136(3):289-92. doi: 10.3109/00016489.2015.1110751. Epub 2015 Nov 25.
OBJECTIVE: This study was designed to determine if hearing status monitoring during intravenous infusion of EA reduces individual variability and to evaluate the correlation between EA dose and Bwt.
2.High LEF1 expression predicts adverse prognosis in chronic lymphocytic leukemia and may be targeted by ethacrynic acid.
Wu W1, Zhu H1, Fu Y1, Shen W1, Miao K1, Hong M1, Xu W1, Fan L1, Young KH2, Liu P1,3, Li J1. Oncotarget. 2016 Feb 29. doi: 10.18632/oncotarget.7795. [Epub ahead of print]
Aberrant activation of lymphoid enhancer-binding factor-1 (LEF1) has been identified in several cancers, including chronic lymphocytic leukemia (CLL). As a key transcription factor of the Wnt/β-catenin pathway, LEF1 helps to regulate important genes involved in tumor cell death mechanisms. In this study, we determined LEF1 gene expression levels in CLL (n = 197) and monoclonal B-cell lymphocytosis (MBL) (n = 6) patients through real-time RT-PCR. LEF1 was significantly up-regulated in both MBL and CLL patients compared with normal B cells. Treatment-free survival (TFS) time and overall survival (OS) time were much longer in CLL patients with low LEF1 expression than in those with high LEF1 levels. Furthermore, Wnt inhibitor ethacrynic acid (EA) induced both apoptosis and necroptosis in primary CLL cells. EA also enhanced the cytotoxicity of both fludarabine and cyclophosphamide against CLL cells in vitro. Finally, we demonstrated that EA functions by inhibiting the recruitment of LEF1 to DNA promoters and restoring cylindromatosis (CYLD) expression in CLL cells.